You are here: Industry Insights > blood cancer

News List

Blood cancer care needs improving, finds MP inquiry pharmatimes
January 18, 2018
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Novartis’ Kymriah shows durable response in blood cancer pharmatimes
December 12, 2017
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
FDA Approves Seattle Genetics' Adcetris to Treat Disfiguring Blood Cancer biospace
November 10, 2017
Seattle Genetics Announces FDA Approval of ADCETRIS (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
FDA approved revolutionary immunotherapy for blood cancer patients biospectrumasia
September 04, 2017
LLS invested more than $20 million in research for this ground-breaking advance over the past two decades through multiple grants awarded to Carl June, M.D
Pfizer wins approval for blood cancer drug Besponsa fiercepharma
August 18, 2017
Pfizer has won FDA approval of a new drug to treat acute lymphoblastic leukemia.
Arthritis drug may treat blood cancer patients expressbpd
August 07, 2017
University of Sheffield scientists discover drug which offers an affordable and effective treatment
New antibody for effective blood cancer treatment using two-pronged approach biospectrumasia
June 23, 2017
The findings of multiple in vivo preclinical studies indicate that this therapy could potentially treat multiple cancers.
EC approves Sandoz’s Rixathon for blood cancer and immunological diseases pharmaceutical-technology
June 21, 2017
Novartis division Sandoz’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe.
New drug combination targets aggressive blood cancer firstwordpharma
March 09, 2017
Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial

Previous page 1 2 3 Next page